PARP-话题@MedSci

#PARP#

95篇内容 | 2634人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621397, encodeId=11cd162139e52, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, objectType=article, longId=724862, objectId=9d1fe248622b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d1fe248622b, replyNumber=0, likeNumber=101, createdTime=2022-04-25, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d1fe248622b, moduleTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d1fe248622b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621396, encodeId=46dd162139622, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, objectType=article, longId=724127, objectId=b5ebe2412785, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5ebe2412785, replyNumber=0, likeNumber=99, createdTime=2022-04-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5ebe2412785, moduleTitle=Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5ebe2412785)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621394, encodeId=6905162139410, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, objectType=article, longId=724027, objectId=af24e240278a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af24e240278a, replyNumber=0, likeNumber=0, createdTime=2022-04-13, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af24e240278a, moduleTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af24e240278a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621395, encodeId=f4b2162139515, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=61, createdTime=2022-04-12, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621393, encodeId=ea8e1621393ca, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=95, createdTime=2022-04-04, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621392, encodeId=23f816213924a, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=78, createdTime=2022-04-04, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621391, encodeId=f81e162139121, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, objectType=article, longId=299624, objectId=273529962455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=273529962455, replyNumber=0, likeNumber=81, createdTime=2022-02-26, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=273529962455, moduleTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=273529962455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621390, encodeId=68151621390c0, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=96, createdTime=2021-12-11, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621389, encodeId=316516213895c, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, objectType=article, longId=221549, objectId=315622154982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=315622154982, replyNumber=0, likeNumber=108, createdTime=2021-12-06, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=315622154982, moduleTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=315622154982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621388, encodeId=269c1621388d2, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, objectType=article, longId=219842, objectId=267d219842d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267d219842d5, replyNumber=0, likeNumber=78, createdTime=2021-11-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267d219842d5, moduleTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=267d219842d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621387, encodeId=8423162138ef1, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=103, createdTime=2021-10-30, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621386, encodeId=ed371621386ce, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=上皮性卵巢癌PARP抑制剂相关生物标志物有哪些？重点归纳！, objectType=article, longId=218423, objectId=5081218423dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5081218423dc, replyNumber=0, likeNumber=84, createdTime=2021-10-13, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5081218423dc, moduleTitle=上皮性卵巢癌PARP抑制剂相关生物标志物有哪些？重点归纳！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5081218423dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621385, encodeId=dd9c1621385ac, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=70, createdTime=2021-08-13, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621384, encodeId=858c162138465, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, objectType=article, longId=214609, objectId=4c4421460961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c4421460961, replyNumber=0, likeNumber=77, createdTime=2021-07-23, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c4421460961, moduleTitle=Clin Cancer Res：PARPi Veliparib联合卡铂和依托泊苷治疗晚期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c4421460961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621383, encodeId=4fe0162138359, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=百济神州PARP抑制剂获批，市场格局竞争加剧, objectType=article, longId=210937, objectId=9edb21093e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9edb21093e61, replyNumber=0, likeNumber=113, createdTime=2021-05-09, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9edb21093e61, moduleTitle=百济神州PARP抑制剂获批，市场格局竞争加剧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9edb21093e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621382, encodeId=0e6116213823a, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle= 重磅！国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批, objectType=article, longId=210714, objectId=1c60210e1466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c60210e1466, replyNumber=0, likeNumber=80, createdTime=2021-05-02, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c60210e1466, moduleTitle= 重磅！国内最佳治疗铂敏感及铂耐药复发性卵巢癌的PARP抑制剂帕米帕利获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c60210e1466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621381, encodeId=aa16162138110, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Cell Death Differ：PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂, objectType=article, longId=206760, objectId=b803206e60e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b803206e60e1, replyNumber=0, likeNumber=69, createdTime=2021-02-05, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b803206e60e1, moduleTitle=Cell Death Differ：PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b803206e60e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621380, encodeId=ba9f16213800a, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=上皮性卵巢癌化疗和PARPi治疗相关血液学毒副作用：临床表现，诊断和管理, objectType=article, longId=206531, objectId=7bc9206531c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bc9206531c8, replyNumber=0, likeNumber=116, createdTime=2021-02-02, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bc9206531c8, moduleTitle=上皮性卵巢癌化疗和PARPi治疗相关血液学毒副作用：临床表现，诊断和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bc9206531c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621379, encodeId=d79016213e91f, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Br J Cancer：靶向细胞自噬作用改善乳腺癌治疗中PARP抑制剂耐药性的产生, objectType=article, longId=206264, objectId=d31420626466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31420626466, replyNumber=0, likeNumber=93, createdTime=2021-01-27, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31420626466, moduleTitle=Br J Cancer：靶向细胞自噬作用改善乳腺癌治疗中PARP抑制剂耐药性的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31420626466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621378, encodeId=678b16213e89c, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, objectType=article, longId=204928, objectId=dd4e20492868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd4e20492868, replyNumber=0, likeNumber=80, createdTime=2020-12-29, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4e20492868, moduleTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4e20492868)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP

2020-05-29

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益

2022-04-25

智者为医08 (审核中...)

前往app查看评论内容

#PARP#

Rhizen Pharmaceuticals AG在AACR 2022公布其差异化的PARP和DHODH抑制剂项目的数据

2022-04-14

lishiwen (审核中...)

前往app查看评论内容

#PARP#

AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布

2022-04-13

lishiwen (审核中...)

前往app查看评论内容

#PARP#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-04-04

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-04-04

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病

2022-02-26

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2021-12-11

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效

2021-12-06

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药

2021-11-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2021-10-30

lishiwen (审核中...)

前往app查看评论内容

#PARP#

上皮性卵巢癌PARP抑制剂相关生物标志物有哪些？重点归纳！

2021-10-13

lishiwen (审核中...)